- Previous Close
70.44 - Open
69.80 - Bid 49.83 x 100
- Ask 87.18 x 100
- Day's Range
67.75 - 70.42 - 52 Week Range
55.00 - 177.37 - Volume
612,497 - Avg. Volume
1,743,381 - Market Cap (intraday)
2.309B - Beta (5Y Monthly) 2.12
- PE Ratio (TTM)
64.09 - EPS (TTM)
1.07 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
102.86
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
www.transmedics.comRecent News: TMDX
View MorePerformance Overview: TMDX
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TMDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TMDX
View MoreValuation Measures
Market Cap
2.31B
Enterprise Value
2.49B
Trailing P/E
64.09
Forward P/E
45.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.47
Price/Book (mrq)
10.10
Enterprise Value/Revenue
5.64
Enterprise Value/EBITDA
35.60
Financial Highlights
Profitability and Income Statement
Profit Margin
8.03%
Return on Assets (ttm)
3.10%
Return on Equity (ttm)
19.39%
Revenue (ttm)
441.54M
Net Income Avi to Common (ttm)
35.46M
Diluted EPS (ttm)
1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
336.65M
Total Debt/Equity (mrq)
226.72%
Levered Free Cash Flow (ttm)
-102.77M